Browsing by Author Cassidy, J

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2012Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin CSimes, Robert John; Tebbutt, Niall; Wilson, Catherine; Zannino, Diana; Ackland, Stephen P.; Broad, A; Cassidy, J; Ganju, V.; Price, Timothy; Robinson, B; Van Hazel, Guy Arthur; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials CentreBevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C, Annals of Oncology, vol.23, 6, 2012,pp 1531-1536
2008Potential regional differences for the tolerability profiles of fluoropyrimidinesClarke, Stephen; Allegra, C; Cassidy, J; Cunningham, David; et al, not known; Haller, D M; Hoff, P; Rothenberg, M; Saltz, Leonard B.; Concord Clinical School: ANZAC Research InstitutePotential regional differences for the tolerability profiles of fluoropyrimidines, Journal of Clinical Oncology, vol.26,(13),2008,pp 2118-2123
2011XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated resultsClarke, Stephen; Cassidy, J; Diaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, Leonard B.; Scheithauer, W; Wong, R; Northern Clinical School: Kolling InstituteXELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, British Journal of Cancer, vol.105, 1 Spring 2010, 2011,pp 58-64